 HOLON, Israel, June 1, 2021 PRNewswire -- Compugen Ltd. Nasdaq: CGEN, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that members of its senior management team will participate in a virtual event to discuss data from its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, as a monotherapy and in combination with nivolumab. 